C9 - complement C9 Gene
Species: Rattus norvegicus
Gene Type: protein coding
Gene ID: 117512
Summary
Involved in blood coagulation. Predicted to be located in extracellular space and plasma membrane. Predicted to be part of membrane attack complex. Biomarker of polycystic kidney disease. Human ortholog(s) of this gene implicated in age related macular degeneration 15 and complement component 9 deficiency. Orthologous to human C9 (complement C9). [provided by Alliance of Genome Resources, Apr 2022]
C9 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_057146.2 | NP_476487.2 | complement component C9 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
complement component C9 |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(17)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-17356 | Fenofibrate | 99.97% | Yes | |
| HY-B0113 | Omeprazole | Inhibitor | 99.96% | Yes |
| HY-N6972 | Cepharanthine | 99.87% | Yes | |
| HY-B1218 | Sulfaphenazole | Inhibitor | 99.85% | Unkown |
| HY-B0258 | Gemfibrozil | 99.91% | Yes | |
| HY-11103 | Sitaxsentan sodium | 98.83% | Unkown | |
| HY-100386 | Ticlopidine | Inhibitor | 99.74% | Unkown |
| HY-B0113A | Omeprazole sodium | Inhibitor | 99.10% | Yes |
| HY-13463 | Avatrombopag | Agonist | 99.83% | Yes |
| HY-B0153A | Ticlopidine hydrochloride | Inhibitor | 99.99% | Unkown |
| HY-13463A | Avatrombopag maleate | 99.99% | Yes | |
| HY-B0113R | Omeprazole (Standard) | Inhibitor | 99.86% | Unkown |
| HY-13463B | Avatrombopag hydrochloride | Agonist | 97.05% | Yes |
| HY-B1376 | Methsuximide | 99.68% | Unkown | |
| HY-76520 | Sitaxsentan | 98.96% | Unkown | |
| HY-109546 | Omeprazole magnesium | Inhibitor | / | Unkown |
| HY-111654 | Diflucortolone | / | Unkown |
Clinical Phase
Bioactive Molecules
(10)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-132581 | Tadnersen | Inhibitor | 99.30% | Phase 3 |
| HY-121872 | DP-b99 | Inhibitor | 95.0% | Phase 3 |
| HY-N1201 | Apigenin | 99.22% | Phase 2 | |
| HY-13024 | Rebastinib | 99.84% | Phase 2 | |
| HY-106379 | Lurosetron | Antagonist | / | Phase 2 |
| HY-19397 | BMS-223131 | / | Phase 2 | |
| HY-15565 | APD668 | 99.73% | Phase 1 | |
| HY-15566 | APD597 | Agonist | 99.97% | Phase 1 |
| HY-114415 | AWZ1066S | Inhibitor | 98.64% | Phase 1 |
| HY-12946A | BI 653048 phosphate | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(248)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-N0904 | Ginsenoside C-K | Inhibitor | 99.93% | Unkown |
| HY-N0893 | Tetrahydrocurcumin | 98.96% | Unkown | |
| HY-15550 | 4'-Hydroxy diclofenac | 99.70% | Unkown | |
| HY-N0043 | Ginsenoside Rd | Inhibitor | 99.88% | Unkown |
| HY-15550S | 4'-Hydroxy diclofenac-d4 | 98.92% | Unkown | |
| HY-W013268 | (S)-(+)-N-3-Benzylnirvanol | Inhibitor | 99.76% | Unkown |
| HY-103661 | BI-6C9 | Inhibitor | 98.47% | Unkown |
| HY-N0762 | Isobavachin | 99.88% | Unkown | |
| HY-N1446S | Oleic acid-13C | 99.99% | Unkown | |
| HY-D1422 | ER Tracker Yellow | 96.91% | Unkown | |
| HY-114759 | MS-PPOH | Inhibitor | 99.05% | Unkown |
| HY-117026 | LKY-047 | Inhibitor | 99.94% | Unkown |
| HY-153898 | rTRD01 | Ligand | 99.10% | Unkown |
| HY-100738 | Ubiquitin Isopeptidase Inhibitor I, G5 | Inducer | 98.0% | Unkown |
| HY-N0473S3 | L-Tyrosine-13C9 | 99.81% | Unkown | |
| HY-N0215S10 | L-Phenylalanine-13C9 | Antagonist | 98.09% | Unkown |
| HY-100641 | 4-Hydroxytolbutamide | 99.69% | Unkown | |
| HY-N1201R | Apigenin (Standard) | 98.82% | Unkown | |
| HY-170538 | SNT-5382 | Inhibitor | 99.96% | Unkown |
| HY-18063 | ML252 | Inhibitor | 99.9% | Unkown |
| HY-117389 | Homocarbonyltopsentin | 99.82% | Unkown | |
| HY-W140827 | Boc-C9-Br | / | Unkown | |
| HY-N0215S11 | L-Phenylalanine-13C9,15N | Antagonist | 99.42% | Unkown |
| HY-N0920 | Dihydrokavain | Inhibitor | 99.94% | Unkown |
| HY-B0158S7 | Cytidine-13C9 | Chemical | 98.69% | Unkown |
| HY-W013175S2 | Uridine 5'-monophosphate-13C9,15N2 disodium | Activator | 99.77% | Unkown |
| HY-139345 | (S,R,S)-AHPC-CO-C9-acid | Chemical | 95.00% | Unkown |
| HY-N1050 | Zederone | Inhibitor | 99.61% | Unkown |
| HY-100641S | 4-Hydroxytolbutamide-d9 | 99.29% | Unkown | |
| HY-132581A | Tadnersen sodium | Inhibitor | 99.30% | Unkown |
| HY-42034 | Hydroquinine | 99.87% | Unkown | |
| HY-W751165 | Uridine-13C9,15N2 | 98.88% | Unkown | |
| HY-113359AS2 | Uridine 5'-diphosphate-13C9,15N2 dilithium | Agonist | 99.5% | Unkown |
| HY-125818S3 | Cytidine-5'-triphosphate-13C9 dilithium | 98.02% | Unkown | |
| HY-14362 | GSK-25 | Inhibitor | 98.33% | Unkown |
| HY-148822 | Nampt activator-2 | Activator | 98.79% | Unkown |
| HY-N0911 | Rehmannioside A | 99.95% | Unkown | |
| HY-W108995 | Boc-C9-COOH | ≥97.0% | Unkown | |
| HY-128859 | EMT inhibitor-2 | Inhibitor | 98.83% | Unkown |
| HY-B1449S11 | Uridine-13C9 | 96.8% | Unkown | |
| HY-116862 | Dibenzylfluorescein | 99.54% | Unkown | |
| HY-B0113S | Omeprazole-d3 | Inhibitor | 98.99% | Unkown |
| HY-147294 | Nivasorexant | 99.74% | Unkown | |
| HY-144652 | IDO1-IN-19 | Inhibitor | 98.82% | Unkown |
| HY-17356R | Fenofibrate (Standard) | 99.92% | Unkown | |
| HY-B0258R | Gemfibrozil (Standard) | 99.82% | Unkown | |
| HY-N7057S3 | Nonanoic acid-d2 | 98.0% | Unkown | |
| HY-W009162S5 | Cytidine 5′-monophosphate-13C9,15N3 dilithium | 99.80% | Unkown | |
| HY-N11222 | Nonanoylcarnitine | 99.87% | Unkown | |
| HY-W587878 | Thujopsene | 86.31% | Unkown | |
| HY-12946 | BI 653048 | Inhibitor | 99.84% | Unkown |
| HY-17356S | Fenofibrate-d6 | 99.70% | Unkown | |
| HY-B0113S3 | Omeprazole-13C,d3 | Inhibitor | 98.00% | Unkown |
| HY-N1201S | Apigenin-d5 | 98.90% | Unkown | |
| HY-N5132 | (-)-Fenchone | 98.0% | Unkown | |
| HY-Y0123S | L-Tyrosine-13C9,15N | 98.0% | Unkown | |
| HY-107372S2 | Uridine triphosphate-13C9 dilithium | 99.33% | Unkown | |
| HY-161943 | NEU3-IN-1 | 99.78% | Unkown | |
| HY-170510 | GB2095 | Inhibitor | 98.92% | Unkown |
| HY-D0184S3 | 2'-Deoxycytidine-13C9,15N3 | 98.74% | Unkown | |
| HY-N8382 | Chalepensin | Inhibitor | 98.98% | Unkown |
| HY-15550S1 | 4'-Hydroxy diclofenac-13C6 | 99.21% | Unkown | |
| HY-W018801 | 5-Nitroisoquinoline | 99.38% | Unkown | |
| HY-A0070AS1 | Liothyronine-13C9,15N | / | Unkown | |
| HY-W009216S1 | 2'-Deoxycytidine-5'-monophosphate-13C9,15N3 dilithium | 99.8% | Unkown | |
| HY-B0258S | Gemfibrozil-d6 | 98.71% | Unkown | |
| HY-101399S | γ-Glu-(Phe-13C9,15N) | / | Unkown | |
| HY-107372S | Uridine triphosphate-13C9,15N2 sodium | / | Unkown | |
| HY-124352 | 2-Nonyl-3-hydroxy-4-quinolone | 98.0% | Unkown | |
| HY-131495 | (S)-6-O-Desmethylnaproxen | Inhibitor | 95.73% | Unkown |
| HY-138527 | Thiol-C9-PEG4 | 99.06% | Unkown | |
| HY-155265 | Pomalidomide-5-C9-NH2 hydrochloride | 98.68% | Unkown | |
| HY-156159 | Thalidomide-NH-C9-NH2 hydrochloride | Inducer | 99.88% | Unkown |
| HY-U00048 | Bucolome | Inhibitor | 98.93% | Unkown |
| HY-W141374 | CB096 | 98.72% | Unkown | |
| HY-Z2667 | (R)-Esomeprazole | Modulator | 96.41% | Unkown |
| HY-101399SA | γ-Glu-(Phe-13C9,15N) TFA | 99.74% | Unkown | |
| HY-117160 | 4-trans-Hydroxy-glibenclamide | Inhibitor | 99.0% | Unkown |
| HY-132581E | Scrambled Tadnersen | Control | / | Unkown |
| HY-159191S | VQPGQN(Phe-13C9,15N)HMFTKEKLEEVIKDI TFA | 95.41% | Unkown | |
| HY-18063A | ML252 hydrochloride | Inhibitor | 98.5% | Unkown |
| HY-B0158S5 | Cytidine-13C9,15N3 | 98.9% | Unkown | |
| HY-N6023 | Thermopsoside | 98.0% | Unkown | |
| HY-172177 | ROCK/HDAC-IN-2 | / | Unkown | |
| HY-13024A | Rebastinib tosylate | / | Unkown | |
| HY-135390 | Hydroxy desmethyl Bosentan | / | Unkown | |
| HY-100386S | Ticlopidine-d4 | Inhibitor | / | Unkown |
| HY-100641S1 | 4-Hydroxytolbutamide-d9-1 | / | Unkown | |
| HY-101400S2 | Deoxycytidine triphosphate-13C9,15N3 dilithium | Activator | / | Unkown |
| HY-101400S4 | Deoxycytidine triphosphate-13C9 dilithium | Activator | / | Unkown |
| HY-101981S3 | Uridine 5'-monophosphate-13C9,15N2 dilithium | Activator | / | Unkown |
| HY-101981S4 | Uridine 5'-monophosphate-13C9 dilithium | Activator | / | Unkown |
| HY-105408A | Fandosentan potassium | / | Unkown | |
| HY-10575 | MK-5596 | / | Unkown | |
| HY-105828 | Sulfamethylphenazole | Inhibitor | / | Unkown |
| HY-111906 | SCYX-6759 | Inhibitor | / | Unkown |
| HY-113359AS1 | Uridine 5'-diphosphate-13C9 dilithium | Agonist | / | Unkown |
| HY-113400S1 | Cytidine diphosphate-13C9 dilithium | / | Unkown | |
| HY-113400S2 | Cytidine diphosphate-13C9,15N3 dilithium | 99.7% | Unkown | |
| HY-113887 | Prostaglandin F1β | Agonist | / | Unkown |
| HY-113887A | 11β-Prostaglandin F1β | Control | / | Unkown |
| HY-116095 | CypD-IN-5 | Inhibitor | / | Unkown |
| HY-116601 | 6-Hydroxywarfarin | 99.87% | Unkown | |
| HY-116811 | AZ-11665362 | / | Unkown | |
| HY-119781 | Kaitocephalin | Antagonist | / | Unkown |
| HY-119996 | AR-C141990 | Inhibitor | / | Unkown |
| HY-121698 | GW694481 | Inhibitor | / | Unkown |
| HY-122163 | MK-3901 | / | Unkown | |
| HY-132581C | Scrambled Tadnersen sodium | Control | / | Unkown |
| HY-13463BS | Avatrombopag-d8 hydrochloride | Agonist | / | Unkown |
| HY-138517 | Thiol-C9-PEG7 | / | Unkown | |
| HY-138526 | Thiol-C9-PEG4-acid | / | Unkown | |
| HY-138528 | Thiol-C9-PEG5-acid | / | Unkown | |
| HY-138529 | Thiol-C9-PEG5 | / | Unkown | |
| HY-138586S | DMT-dC(ac) Phosphoramidite-13C9, 15N3 | / | Unkown | |
| HY-141547 | Nav1.7-IN-8 | Inhibitor | / | Unkown |
| HY-141878 | di-Ellipticine-RIBOTAC | / | Unkown | |
| HY-141878A | di-Ellipticine-RIBOTAC TFA | / | Unkown | |
| HY-141913S | 3-Chlorotyrosine-13C9, 15N hydrochloride | / | Unkown | |
| HY-143906 | URAT1 inhibitor 2 | Inhibitor | / | Unkown |
| HY-145490 | trans-Hydroxy Glimepiride | / | Unkown | |
| HY-147807 | HIV-1 inhibitor-40 | Inhibitor | / | Unkown |
| HY-148597 | FGFR-IN-10 | Inhibitor | / | Unkown |
| HY-149566 | Thalidomide-5-O-C9-NH2 hydrochloride | Inducer | 99.57% | Unkown |
| HY-149572 | Thalidomide-4-O-C9-NH2 hydrochloride | Inducer | 99.89% | Unkown |
| HY-149866 | HIV-1 inhibitor-58 | Inhibitor | / | Unkown |
| HY-150710S | Cytidine 5'-triphosphate-13C9,15N3 ammonium | / | Unkown | |
| HY-151251 | CYP2C9/CYP2C19-IN-1 | Inhibitor | / | Unkown |
| HY-151253 | CYP2C1/CYP2C19-IN-2 | Inhibitor | / | Unkown |
| HY-153371 | 50-C2-C9-4tail | / | Unkown | |
| HY-153970 | URAT1 inhibitor 7 | Inhibitor | 98.01% | Unkown |
| HY-156133 | Dihydrospinosyn A aglycone | / | Unkown | |
| HY-159143 | BChE-IN-33 | Inhibitor | / | Unkown |
| HY-160555 | (S,R,S)-AHPC-CO-C9-NH2 | / | Unkown | |
| HY-160555A | (S,R,S)-AHPC-CO-C9-NH2 hydrochloride | 98.79% | Unkown | |
| HY-163208 | VH 032 amide-alkylC9-amine hydrochloride | / | Unkown | |
| HY-163816 | Antiproliferative agent-53-d3 | Inhibitor | / | Unkown |
| HY-164031A | Cloperidone hydrochloride | Inhibitor | / | Unkown |
| HY-164111 | JNK-IN-17 | Inhibitor | / | Unkown |
| HY-166530S | Ticlopidine-d6 hydrochloride | Inhibitor | / | Unkown |
| HY-166934S | Endosulfan-13C9 sulfate | / | Unkown | |
| HY-167872 | Bifeprofen | Inhibitor | / | Unkown |
| HY-168235 | (S,R,S)-AHPC-Me-amide-C9-acid | Degrader | / | Unkown |
| HY-168277 | 5-Aminothalidomide-C9-Boc | / | Unkown | |
| HY-169095 | (S,R,S)-AHPC-Me-CO-C9-NH2 | / | Unkown | |
| HY-171722 | Ascr#10 | Activator | / | Unkown |
| HY-171837 | c9,t11,c15-CLNA | Activator | / | Unkown |
| HY-172897 | EGFR/DHFR-IN-2 | / | Unkown | |
| HY-172902 | RNA binder 1 | / | Unkown | |
| HY-173032 | VU6033685 | Agonist | / | Unkown |
| HY-17356G | Fenofibrate (GMP) | / | Unkown | |
| HY-17356S1 | Fenofibrate-d4 | / | Unkown | |
| HY-175447 | GDC-0152-amide-PEG2-acid | / | Unkown | |
| HY-175887 | Pomalidomide-C9-Br | / | Unkown | |
| HY-175977 | BnO-CO-O-C9-O-COOH | / | Unkown | |
| HY-176737 | TGF-β1/Smad-IN-1 | Inhibitor | / | Unkown |
| HY-176905 | Tacedinaline-C9-acid | / | Unkown | |
| HY-177070 | Angexostat | Inhibitor | / | Unkown |
| HY-178479 | IDO1-IN-30 | / | Unkown | |
| HY-178786 | RET-IN-31 | Inhibitor | / | Unkown |
| HY-179154 | α-Glucosidase-IN-101 | Inhibitor | / | Unkown |
| HY-181321 | Thalidomide-4-O-C9-Br | / | Unkown | |
| HY-181611 | Polθ-IN-10 | / | Unkown | |
| HY-181662 | DLK-IN-2 | Inhibitor | / | Unkown |
| HY-181747 | CYP11A1-IN-3 | Inhibitor | / | Unkown |
| HY-182602 | KOSN 1724 | Inhibitor | / | Unkown |
| HY-182890 | Thalidomide-5-NH-C9-acid | / | Unkown | |
| HY-183017 | N-Descyclopropanecarbaldehyde olaparib-CO-C9-NHBoc | / | Unkown | |
| HY-18341S3 | L-Thyroxine-13C9,15N | / | Unkown | |
| HY-184233 | C9S | Degrader | / | Unkown |
| HY-187080 | cGAS-IN-5-CH2-amido-C9-NH2 | / | Unkown | |
| HY-187136 | EZH2-IN-13-CO-C9-COOH | / | Unkown | |
| HY-79131S1 | Fmoc-Phe-OH-13C9,15N | 99.33% | Unkown | |
| HY-B0113S1 | Omeprazole-d3-1 | Inhibitor | 95.09% | Unkown |
| HY-B0153AS | Ticlopidine-d4 hydrochloride | Inhibitor | / | Unkown |
| HY-B1218S | Sulfaphenazole-d4 | 99.66% | Unkown | |
| HY-B1422S | 9-Aminoacridine-13C6 | Inhibitor | / | Unkown |
| HY-D0184S5 | 2'-Deoxycytidine-13C9 | 96.8% | Unkown | |
| HY-E72098 | Human CYP2C9, Reductase+b5 | / | Unkown | |
| HY-N0043R | Ginsenoside Rd (Standard) | Inhibitor | 99.92% | Unkown |
| HY-N0215S9 | L-Phenylalanine-13C9,15N,d8 | Antagonist | / | Unkown |
| HY-N0893S | Tetrahydrocurcumin-d6 | / | Unkown | |
| HY-N0904R | Ginsenoside C-K (Standard) | Inhibitor | / | Unkown |
| HY-N1201S1 | Apigenin-13C | / | Unkown | |
| HY-P0073S | Tyr-Gly-Gly-{Phe-13C9,15N}-Met-OH TFA | / | Unkown | |
| HY-P5538S | EPYFGYSGAFK-13C9,15N3 TFA | / | Unkown | |
| HY-RS00534 | AKR1C1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS01759 | C9 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS01760 | C9orf72 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS01761 | C9orf78 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03460 | CYP2C9 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W009216S4 | 2'-Deoxycytidine-5'-monophosphate-13C9 dilithium | 99.5% | Unkown | |
| HY-W011090S | ((2R,3S,4R,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl phosphate-13C9,15N3 sodium | / | Unkown | |
| HY-W015007S | Metyrosine-13C9,15N,d7 | Inhibitor | / | Unkown |
| HY-W018386AS | 3-Bromo-L-tyrosine-13C9,15N TFA | / | Unkown | |
| HY-W018386S1 | 3-Bromo-L-tyrosine-13C9 | / | Unkown | |
| HY-W042357S4 | Ac-rC Phosphoramidite-13C9 | / | Unkown | |
| HY-W042357S6 | Ac-rC Phosphoramidite-13C9,15N3 | / | Unkown | |
| HY-W048482S1 | rU Phosphoramidite-13C9,15N2 | / | Unkown | |
| HY-W048482S2 | rU Phosphoramidite-13C9 | / | Unkown | |
| HY-W127393 | N-Nonanoyl-L-homoserine lactone | / | Unkown | |
| HY-W140208 | 3-Phenylthiophene | Inhibitor | / | Unkown |
| HY-W663179 | DNDI-VL-2098 | Inhibitor | / | Unkown |
| HY-W707554 | Ticlopidine hydrochloride-d6 | / | Unkown | |
| HY-W753181 | (S)-2-Hydroxy-3-phenylpropanoic acid-13C9 | / | Unkown | |
| HY-105828A | Sulfamethylphenazole sodium | Inhibitor | / | Unkown |
| HY-105828B | Sulfamethylphenazole potassium | Inhibitor | / | Unkown |
| HY-117925 | Personalised postprandial-targeting | Inhibitor | / | Unkown |
| HY-124209 | 9-keto Fluprostenol | / | Unkown | |
| HY-124352S | 2-Nonyl-3-hydroxy-4-quinolone-d4 | / | Unkown | |
| HY-132399S | Methsuximide-d5 | / | Unkown | |
| HY-134999 | 10-Hydroxywarfarin | Inhibitor | 99.9% | Unkown |
| HY-150712S | Uridine triphosphate-13C9,15N2 dilithium | / | Unkown | |
| HY-164031 | Cloperidone | Inhibitor | / | Unkown |
| HY-169119 | Antifungal agent 114 | Inhibitor | / | Unkown |
| HY-169735 | Aurora A inhibitor 4 | Inhibitor | / | Unkown |
| HY-170367 | Antimicrobial agent-35 | Inhibitor | / | Unkown |
| HY-172335 | C9-200 | / | Unkown | |
| HY-17356S2 | Fenofibrate-13C6 | / | Unkown | |
| HY-175169 | Urease-IN-21 | Inhibitor | / | Unkown |
| HY-178479A | (Rac)-IDO1-IN-30 | / | Unkown | |
| HY-180227 | URAT1-IN-15 | Inhibitor | / | Unkown |
| HY-180273 | Antibacterial agent 309 | Inhibitor | / | Unkown |
| HY-182965 | Glucocorticoid receptor antagonist-1 | / | Unkown | |
| HY-182976 | Tenovin-3-CO-C9-NH2 | / | Unkown | |
| HY-184843 | 4-Methoxywarfarin | Inhibitor | / | Unkown |
| HY-184883 | VU6035406 | Inhibitor | / | Unkown |
| HY-76520S | Sitaxsentan-13C6 | / | Unkown | |
| HY-B0113S2 | Omeprazole sulfone (methoxy-d3) | Inhibitor | 99.70% | Unkown |
| HY-B0113S4 | Omeprazole-d3 sodium | Inhibitor | / | Unkown |
| HY-B0113S5 | Omeprazole-d6 | Inhibitor | / | Unkown |
| HY-B0258S1 | Gemfibrozil-d6-1 | / | Unkown | |
| HY-N12962 | 11S(12R)-EET | / | Unkown | |
| HY-N12962A | 11R(12S)-EET | / | Unkown | |
| HY-N7482 | Pyranocoumarin | / | Unkown | |
| HY-P0036S3 | Octreotide-13C9,15N | / | Unkown | |
| HY-RS17317 | C9 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS20470 | Psma4 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS21991 | C9orf72 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23772 | C9 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W008016S | Fmoc-Tyr(tBu)-OH-13C9,15N | 98.8% | Unkown | |
| HY-W009162S1 | Cytidine 5′-monophosphate-13C9 dilithium | / | Unkown | |
| HY-W413619 | Cipargamin enantiomer | Inhibitor | / | Unkown |
| HY-W440809 | Nonyl 8-bromooctanoate | / | Unkown | |
| HY-W739842 | 8-Hydroxywarfarin | Inhibitor | 95.0% | Unkown |
| HY-W753927 | 9(Z),12(E)-Octadecadienoic Acid | / | Unkown | |
| HY-W800740 | Nonyl 6-bromohexanoate | / | Unkown | |
| HY-113623 | Pyrenophorol | / | Unkown |
Inhibitory Antibodies
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99141 | Anti-Mouse LAG-3 Antibody (C9B7W) | Inhibitor | 99% | Unkown |
| HY-P990140 | Anti-Rat β-2-Microglobulin Antibody (4C9) | / | Unkown | |
| HY-P990204 | Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service